cyrilzakka/clinical-trials huggingface dataset:
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors

Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials.

The Strata Trial (STR-001-001) has been initiated by Strata Oncology to evaluate the clinical benefit of systematic comprehensive genomic profiling for participants with advanced cancer using real-world data and endpoints, while assessing the proportion of participants available for clinical trials and approved targeted therapies in advanced and/or aggressive cancers. The Strata Trial uses surplus, or leftover, tumor specimens for molecular profiling and does not require additional study-specific procedures.

Participants enrolled on the Strata Trial will submit surplus, clinical formalin-fixed paraffin-embedded (FFPE) tumor specimens for molecular profiling and a test report will be provided back to the investigator. For those participants identified as having molecular alterations associated with a Strata-affiliated therapeutic clinical trial and/or approved targeted therapy or trials, the Strata reports will provide additional relevant information.

All molecular profiling will be performed in the Strata Oncology CAP-accredited and CLIA-certified laboratory (Ann Arbor, MI). The molecular profiling assays will include tumor-only comprehensive genomic profiling (CGP) by next generation sequencing (NGS) of DNA and RNA covering a range of actionable genomic alterations, such as mutations (e.g. those in EGFR and BRAF), copy number alterations (e.g. ERBB2 amplifications), gene expression, gene fusions (e.g. ALK fusions), tumor mutation burden (TMB) and microsatellite instability status, and may include additional integrative DNA and RNA tests over time.

Participants may be followed for treatment changes and survival for three years from the time of enrollment and/or signed informed consent.

Participants may also be eligible for the Strata Trial Sub-Study at applicable Strata Trial sites. This sub-study is a sample collection study to support the development and evaluation of biomarker assays for patients with solid tumors.

Eligibility Criteria:
Inclusion Criteria:

* Subjects must be ≥ 18 years of age.
* Subjects must have histologically documented solid tumors (including lymphoma and multiple myeloma).
* Specific criteria for individual tumor types are as follows:

  1. Participants with gliomas are eligible at any stage of disease
  2. Participants with pancreatic carcinoma are eligible at any stage of disease
  3. Participants with rare tumors (i.e. cancer started in an unusual place in the body, it is unusual type and requires special treatment) are eligible at stages II-IV.
  4. Participants with other tumor types must have recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer.
  5. Participants with other tumor types must have recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer.
* Must have an adequate formalin-fixed paraffin-embedded tumor specimen for genomic sequencing.
Effect of Kinesiotape Technique on Wrist Among Chronic Stroke Patients

The aim of this randomized controlled is to assess the effect of kinesiotape technique upon wrist joint among the patients with chronic stroke. Patients are devided into groups, in group A kinesiotaping facilitation technique is applied on wrist extensor muscles while inhibition technique is applied on wrist flexor muscles and the result is the compared between the groups and within the group.

Stroke is a very common disease worldwide causing severe musculoskeletal disability due to which quality of life of patient compromises, patient becomes dependent of assistance in daily living activities and few becomes bed ridden. Stroke also causes death of the patient. Apart from musculoskeletal issues patient's cognitive abilities are also effected. It is tough to manage these patients as stroke varies in types and symptoms. Symptoms and severity depend upon type of stroke and factors like lifestyle, age and health issues. According to the symptoms different physiotherapy techniques and rehabilitation is used along with medical treatment and counseling of the patient. Kinesiotape also has the advantage that it can be worn 3-5 days due to which it's effects remains for long time as compare to other treatments which are given and has effect for a specific time for example a session of physical therapy including exercises is for an hour but this tape can be worn for days once applied.

Randomized controlled trial was done, 24 patients were recruited according to inclusion exclusion criteria. Patients were further divided into two groups; group 1 was given muscular facilitation treatment for wrist extensors and group 2 was given sessions for muscle inhibition treatment for wrist flexors. 6 sessions were given, 1 session per week over the period of 6 weeks to each patient.

Wrist range of motion for extension, flexion, ulnar and medial deviation was measured using goniometer before and after the 6 weeks. Manual muscle test for wrist extensors, modified ashworth scale and upper limb functional index scoring was done before and after sessions. Data was collected from a private clinic of PWD Rawalpindi.

The statistical values of result showed no significant change in between both the groups, before and after treatment. But a significant improvement was about observed within the group analysis It can be concluded from this study that Kinesiotape is an effective treatment method both in inhibiting and facilitating muscular performance. Hence both treatments were equally effective. it helps in increasing range of motion and in reducing spasticity.

Eligibility Criteria:
Inclusion Criteria:

* Age b/w 40 to 90
* Limited ROM (wrist extension)

Exclusion Criteria:

* Disoriented
* Who needs more then moderate support to achieve basic ADL and are bed bound
* Communication gap
* Allergic to Kinesiotaping after being positive to patch test
Feasibility of a One-day-and-a-half for Patients With Low Back Pain

The purpose of this study was to assess the feasibility of a one-day-and-a-half no intensive multidisciplinary education and exercise therapy program in the subgroup of patients with subacute or chronic LBP for whom first-line treatments had failed but for whom an intensive multidisciplinary rehabilitation program was not indicated.

Retrospectively, data of patients between 18 and 60 years who had benefited in the PMR unit of Cochin' hospital of a one-day-and-a-half no intensive multidisciplinary education and exercise therapy program are collected.

This no intensive multidisciplinary education and exercise therapy program is proposed by the PMR unit of Cochin' hospital to all patients with a subacute or chronic low back pain for whom first-line treatments had failed but for whom an intensive multidisciplinary rehabilitation program is not indicated.

It is done in group of 4 to 6 people, performed by medical doctors with experience in the management of patients with low back pain, physiotherapists, occupational therapists, and psychologist.

Data regarding feasibility of this program were recorded with autoquestionnaires that patients had to fill in during the program and 3 months after.

Eligibility Criteria:
Inclusion Criteria:

* age ≥ 18 years
* subacute or chronic non-specific LBP ≥ 6 weeks
* no indication for an intensive multidisciplinary rehabilitation program according to the senior physician, a specialist in physical medicine and rehabilitation and/or rheumatology with a strong experience in the care of patients with non-specific LBP
* currently working
* written consent

Exclusion Criteria:

* inability to speak or read French
* cognitive impairment
* current sick leave
* history of intensive multidisciplinary rehabilitation program for LBP
Comparison of Vascular Access in STEMI

Distal radial access (DRA) has recently introduced and previous studies have demonstrated that it is feasible option, showing several advantages including less bleeding and access-site complications over proximal radial access (PRA). Previous study reported the feasibility of DRA as an alternative option for primary percutaneous coronary intervention (PCI) in STEMI patients without major complication. However, comparison study of each vascular access for primary PCI have not been conducted until now. Here, The investigators aim to compare the DRA, PRA and femoral access (FA), in terms of feasibility and safety, in patients with STEMI.

This is a retrospective study with patients who underwent primary PCI for STEMI between March 2020 to May 2021. The primary outcome of this study is the access-site complication including major bleeding requiring transfusion or surgery, hematoma and arterial occlusion.

Recently, DRA has gained the interest of interventional cardiologists and previous studies have demonstrated several advantages including patient and operator comfort, shorter hemostasis duration, less bleeding, and access-site complications over PRA. More recently, randomized trial demonstrated that DRA prevents radial artery occlusion after the procedure compared with PRA. From this perspective, DRA could be considered an alternative access route for primary PCI in selected STEMI patients using potent P2Y12 inhibitors such as ticagrelor or prasugrel, or glycoprotein IIb/IIIa inhibitors.

Eligibility Criteria:
Inclusion Criteria:

* Between March 2020 to May 2021, patients who underwent primary PCI for STEMI at the Yongin Severance Hospital

Exclusion Criteria:

* Refractory cardiogenic shock requiring extracorporeal membrane oxygenation (ECMO)
Cognitive Fatigue, Self-Regulation, and Academic Performance: A Physiological Study

This study aims to examine the relationship among cognitive fatigue, self-regulation, and academic performance.

1) Sievertsen et al. (2016) have demonstrated that standardised test performance decreased with every hour later in the day and increased after a break. Hence, we hypothesise that standardised test performance would vary as a function of physiological response during cognitive fatigue. 2) Martin et al. (2019) found that those who participate in more self-regulatory activity were less susceptible to the effects of cognitive fatigue. Hence, we hypothesise that greater self-regulation may moderate the relationship between cognitive fatigue and standardised test performance. Individual differences (i.e., age, gender, caffeine and food intake, body mass index, skin temperature, sleep quality, depression, anxiety, stress, baseline physiology and behavioural performance) will be examined and accounted for.

Eligibility Criteria:
Inclusion Criteria:

* Singapore-based
* Non-clinical
* 18-35years

Exclusion Criteria:

* Individuals with hearing difficulties or failing to meet the minimal threshold for normal hearing
* Individuals with a history of ear, developmental, neurological, or psychiatric disorder
Colostrum from MERS-CoV Seropositive Camels for SARS-CoV-2 Infection - a Placebo-controlled Randomized Trial.

The study aims to study the efficacy of colostrum from MERS-CoV-positive camels applied as a nasal spray to COVID-19 patients for treatment and prevention of SARS-CoV-2 infection. This study will compare the usage of colostrum to placebo.


Eligibility Criteria:
Inclusion Criteria:

* Age over 18 years.
* Laboratory-proven infection with COVID-19 using PCR or another approved kit
* Hospitalized / community setting-at low-moderate clinical risk according to the NEWS-2 scale with a score of 0-10.
* Onset of symptoms up to 7 days before inclusion
* Can sign informed consent
* Willingness and ability to participate in research

Exclusion Criteria:

* Pregnant women or lactating
* Lack of judgment (psychiatric disorder or dementia)
* Immunosuppressed - HIV with CD4 below 500, chemotherapy, steroids - more than 5 mg per day, solid organ transplants, bone marrow transplants, active hematological or oncological malignancies, biological therapy
* Neutropenia (less than 2000 neutrophils per cubic meter) or thrombocytopenia (platelet count less than 50000 per cubic meter).
* Acute or chronic sinusitis.
* Nasal polyps or any pathology in the nasal cavity
* Cystic fibrosis
* Significant disturbance in liver functions (AST/ALT more than 5 times the ULN)
* Significant renal dysfunction (GFR lower than 30 ml per minute)
* Known allergy to colostrum or cow\&#39;s milk
* Use of another study drug
Developing an EEG Probe for Studying and Modulating Cognitive Control

This study aims to investigate effects of transcranial current stimulation (tES) and transcutaneous direct current stimulation (tsDCS) associated changes on fronto-parietal EEG and cognitive performance in patients with post stroke depression (PSD)

The investigators will perform a double blind, randomized, sham controlled, crossover study design to assess effects of tES, tsDCS and sham stimulation on the performance during a cognitive control task. The working Hypothesis is tsDCS and/or tES will enhance frontal theta oscillations as recorded on EEGs and improve task performance compared to sham stimulation.

Results from this project can potentially lead to the development of a new research tool for assessing neuromodulation strategies to treat mental disorders and their comorbidities. It will also uncover the neural correlates of cognitive deficits in PSD and provide feasible biomarkers associated with treatment response in support of a larger clinical.

Eligibility Criteria:
Inclusion Criteria:

1. Subjects will include both male and female of age over 18 years and a BMI of 18-35 Kg/mts2 who have experienced stroke.
2. Moderately depressed, MADRS:18-28, PHQ9: 10-20 and/or experiencing cognitive impairments after stroke

Exclusion Criteria:

1. Current or lifetime bipolar disorder or schizophrenia diagnosis;
2. current (past month): PTSD, psychotic or substance use disorder (nicotine and caffeine allowed);
3. significant risk of suicide according to CSSRS or clinical judgment, or suicidal behavior in the past year:
4. current chronic severe pain conditions;
5. current chronic use of: opioids analgesics, medications that affect blood pressure or drugs with significant autonomic effects (stimulants and antipsychotics allowed if dose stable for 1 month);
6. skin lesions on electrode placement region;
7. implanted electrical medical devices;
8. Pregnancy;
9. suspected IQ\<80, and 10) any other clinically relevant reason as judged by the clinician.
Early Limb Rehabilitation Therapy Within 48 h of Acute Stroke Onset(ERTAS)

This study aimed to evaluate effectiveness of initial limb rehabilitation compare therapy took place within 48h with therapy took place after 48h for patients with stroke (modified Rankin Scale Score 3-4).

Early rehabilitation after stroke is thought to contribute to the effects of stroke-unit care. However, time of initial rehabilitation therapy is poorly defined and not underpinned by strong evidence in patients with stroke (modified Rankin Scale Score 3-4). The investigators do this parallel-group, single-blind, randomized controlled trial in shengjing hospital of China Medical University. Participants (aged≥18 years) with ischaemic or haemorrhagic stroke, first or recurrent, who meet physiological criteria are randomly assigned (1:1), to receive usual stroke therapy. Treatment with recombinant tissue plasminogen activator is allowed. Randomisation is stratified by study site and stroke severity. The primary outcome was a outcome 3 months after stroke, defined as a modified Rankin Scale score of 3-4. The investigators do analysis on an intention-to-treat basis.

Eligibility Criteria:
Inclusion Criteria:

1. Patients were diagnosed acute stroke within 24h onset. Head CT or MRI scans were confirmed the diagnosed.
2. The age was from 18 to 75 years old.
3. Temperature ≤38.0℃，Pulse rate 60-100bpm，Respiratory rate≤24 bpm，systolic blood pressure≤220mmHg.
4. Glasgow score: 9-14.
5. Acute Physiology and Chronic Health Evaluation(APACHE Ⅱ)score: ≤17.
6. National Institutes of Health Stroke Scale (NIHSS)score: \<16. (Upper and lower extremity motor function item score\<8).
7. Modified Rankin Scale score:3-4.
8. There were no serious diseases before, such as heart, liver, kidney and lung diseases.
9. Patients themselves or their nominated representative sign the informed consent form.

Exclusion Criteria:

1. There were unstable vital sign. There were serious organic dysfunction (heart, liver, kidney or lung).
2. Patients with transient ischemic attack.
3. Patients with subarachnoid haemorrhage.
4. Patients with haemorrhage were documented immediate surgery.
5. Pregnancy patients with stroke.
6. During the course of the project, major diseases took place (such as, myocardial infarction, gastrointestinal bleeding, respiratory failure, pulmonary embolism, deep vein thrombosis).
Novel Amblyopia Treatment With Virtual Reality Games

The goal of this study is to compare the change in amblyopic eye acuity between treatment periods in children with amblyopia, aged 5-17 years. The main question it aims to answer is:

Is a 16-week course of amblyopia treatment using Vivid Vision Therapeutic (Dichoptic) Virtual Reality Games for approx. 25 min/day, 6 days/week more effective for improvement in amblyopic-eye VA, binocularity (stereoacuity, suppression, alignment), contrast sensitivity, attention, oculomotor function, visual-motor integration, and quality of life than 16 weeks of continued glasses alone?

Participants will each serve as their own control and complete:

Treatment period 1: Continued optical correction (glasses) alone for 16 weeks; Treatment period 2: Vivid Vision Therapeutic (Dichoptic) Virtual Reality Games for 16 weeks (approx. 25min/day, 6 days/week) plus continued optical correction


Eligibility Criteria:
Inclusion Criteria:

Patients ages 5 to 17 years of age

* Moderate to severe unilateral amblyopia (logMAR best corrected visual acuity 0.3 to 1.3) associated with anisometropia and/or strabismus of ≤5pd
* Age normal VA in the nonamblyopic eye
* Spectacle correction (if required) worn for at least 16 weeks, or until stability of VA is demonstrated (\<0.1 logMAR change by the same testing method measured on 2 exams at least 8 weeks apart)
* Interocular difference of ≥ 3 lines
* No amblyopia treatment in the past 2 weeks
* An interpupillary distance of 52-72 mm (inclusive)

Exclusion Criteria:

* Myopia greater than -6.00 diopters (D) spherical equivalent in either eye.
* Previous intraocular or refractive surgery.
* Previous dichoptic treatment \> 2 weeks in duration
* Ocular co-morbidity that may reduce visual acuity determined by an ocular examination performed within the past 7 months (Note: nystagmus per se does not exclude the participant if the above visual acuity criteria are met).
* Diplopia more than once per week over the last week prior to enrollment by parental report.
* Down syndrome or cerebral palsy.
* Light-induced seizures
* Known simulator sickness
* Severe developmental delay that would interfere with treatment or evaluation (in the opinion of the investigator). Participants with mild speech delay or reading and/or learning disabilities are not excluded.
Physical Activity Barriers in AECOPD

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Patients require good communication with the physician to improve control illness. Shared decision making is a good option to improve physical activity barriers in acute exacerbated COPD patients during the hospitalization period.


Eligibility Criteria:
Inclusion Criteria:

* Inclusion criteria were COPD patients hospitalized due to acute exacerbation

Exclusion Criteria:

* Exclusion criteria were the inability to provide informed consent, the presence of psychiatric or cognitive disorders, progressive neurological disorders, organ failure, cancer, or inability to cooperate. Patients who had experienced another exacerbation of COPD in the previous month were also excluded.
Prospective Longitudinal Multicentric Study to Evaluate Syde® Digital Endpoints in Healthy Adults

The study aims to constitute a longitudinal Syde® digital health technology (DHT) dataset to serve as a healthy adult reference for Syde® digital variables development and validation. Subjects will be assessed every 6 months for 2 years.


Eligibility Criteria:
Inclusion Criteria:

* Male or female aged between 18 and 65 years old
* Signed informed consent
* Subjects with a reported BMI ≥ 17 and ≤ 35
* Subject with unlimited internet connection at home and authorizing automatic data upload
* Subject willing and able to comply with all study procedures including:

  * baseline data and questionnaires data entry on EDC (electronic data capture) throughout the study
  * Syde® related procedures
* Subject confirming to be affiliated to, or beneficiary from, a social security category

Exclusion Criteria:

* Elite athletes (at a national level)
* Pregnant women
* Presence of an orthopedic, neuromuscular, or neurological pathology affecting walking gait quality or requiring a walking aid
* Subjects reporting to have an incapacity or invalidity or to be affected by a chronic disease which can affect their activity and/or their lower limb function
* Subjects reporting to have undergone recent surgical procedures, trauma (within 6 months), or affected by a disease or condition affecting lower limb function within 3 weeks before their inclusion
Video Laryngoscope Versus USB Borescope in Difficult Intubation

Video Laryngoscope Versus a USB Borescope Aided Endotracheal Intubation in Adults With Anticipated Difficult Airway

For patients allocated to the USB-borescope technique, a proper size endotracheal tube will be placed over the USB-borescope (with an external diameter of 5.5 mm) which will be coated externally with water-soluble lubricant. The proper size laryngoscope blade will be inserted. The USB-borescope will be placed through the oral cavity and will be advanced while tracking it on a mobile phone, it will be advanced to the glottic opening. If needed, rotation of USB-borescope and/or external laryngeal manipulation will be used to align it with the vocal cord.

For patients allocated to the intubation over Video Laryngoscope technique, video laryngoscope (Insighters insight is3) proper size blade will be placed and introduction of the Video Laryngoscope till viewing the glottis opening then insertion of a proper sized endotracheal tube

Eligibility Criteria:
Inclusion Criteria:

* 1.American Society of Anesthesiologist ASA physical status I-II patients. 2.Both genders. 3.Age18-60 years old 4.BMI \<35 5.patients with El-Ganzouri score more than or equal to 4

Exclusion Criteria:

* Presence of pulmonary diseases
* Uncontrolled hypertension
* Ischemic heart disease
* Cervical spine fracture
* Limited mouth opening
* known to have tumors or polyps in the upper airway
* History of difficult intubation or difficult bag-mask ventilation
* Patients with difficult bag-mask ventilation after induction of anesthesia